Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [5][28]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 3.41% from October 10 to October 23, 2025, which is approximately 1.22 percentage points lower than the index [4][14]. - Most sub-sectors within the industry recorded negative returns during the same period, with offline pharmacies and traditional Chinese medicine sectors showing positive growth of 4.19% and 1.55%, respectively. In contrast, the medical R&D outsourcing and medical equipment sectors experienced declines of 8.86% and 7.66% [4][17]. - Approximately 56% of stocks in the industry recorded positive returns, while 44% showed negative returns during the reporting period [18]. - The overall industry valuation has decreased, with the SW pharmaceutical and biotechnology index's PE (TTM) at approximately 53.10 times, which is 3.90 times higher than the CSI 300 index [21][28]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 3.41% from October 10 to October 23, 2025 [4][14]. - Most sub-sectors recorded negative returns, with offline pharmacies and traditional Chinese medicine performing better [17]. - About 56% of stocks in the industry had positive returns, indicating some resilience despite overall declines [18]. - The industry valuation has decreased, with a PE ratio of 53.10 times [21]. 2. Industry News - On October 21, the Ministry of Finance announced the allocation of funds for enhancing medical service capabilities, aimed at supporting various healthcare initiatives [22][26]. 3. Important Company Announcements - Junshi Biosciences disclosed that its subsidiary passed an FDA inspection, indicating compliance with current Good Manufacturing Practices [27]. 4. Weekly Industry Perspective - The report suggests focusing on sectors with potential for exceeding expectations in the upcoming quarterly reports, highlighting specific companies across various segments such as medical devices, pharmaceutical commerce, and innovative drugs [5][28][29].

Core Viewpoint - The article emphasizes the importance of standardized clinical trials in the medical aesthetics industry, highlighting the need for scientific design, regulatory compliance, and reliable data to ensure the clinical value of innovative products [2]. Group 1: Clinical Trial Quality Management - The "Good Clinical Practice (GCP)" provides a unified standard for the industry, addressing the increasing complexity and compliance requirements of clinical trials in the medical aesthetics field [2]. - A special forum on "Clinical Trial Quality Management" was established to analyze GCP core points and discuss the implementation and regulatory requirements of medical aesthetics-related trials [2]. Group 2: Forum Details - The second forum on the medical aesthetics industry was successfully held, with the next forum scheduled for October 31 to November 2, 2025, at the Beijing International Conference Center [4]. - The agenda for the Clinical Trial Quality Management forum includes various presentations from experts in the field, covering common issues in clinical trials, high-quality research design, collaboration for effective trials, and ethical review from a legal perspective [5]. Group 3: Participants - The forum is expected to attract a diverse group of participants, including senior lawyers, medical device and aesthetics company representatives, clinical doctors, researchers, investment institution representatives, and regulatory experts [7].

Core Viewpoint - 招银国际 maintains a "Buy" rating for 巨子生物 (02367) with a target price of HKD 58.35, despite a weak online sales performance for 可复美 during the first phase of Double Eleven sales [1] Group 1: Financial Performance - 可复美's online revenue is estimated to decline by 10% year-on-year in 2H25, leading to an overall online revenue growth rate of approximately 5% for the year [1] - 可丽金 is expected to achieve a high growth rate of about 40% in online revenue for the year [1] - The company's revenue growth forecast for 2025 is expected to slow down to 12% [1] - The CAGR for 可复美's revenue growth from 2025E to 2027E has been revised down from 26% to 14.5% due to short-term pressures on online sales [1] Group 2: Product Development - 巨子生物's first injectable recombinant collagen product, recombinant type I α1 collagen lyophilized fiber, has been approved for use in facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - The approval marks the completion of the company's product matrix layout for aesthetic injections, post-surgical recovery (dressing), and functional skincare [1] - The company is progressing with the commercialization of injectable products [1] Group 3: Upcoming Products - The company has two additional injectable collagen products in the approval stage: 1. Injectable recombinant collagen filler for moderate to severe neck wrinkles, prioritized for medical device approval by December 2024 [2] 2. Recombinant collagen implant, submitted for registration as a drug-device combination by August 2025, currently under review [2] - The approval of these products will further enrich the company's aesthetic product matrix, covering a range of anti-aging scenarios from forehead to neck and improving skin texture [2]

Group 1 - The core viewpoint of the report is that Zhuhai International maintains a "Buy" rating for Giant Bio (02367) with a target price of HKD 58.35, despite short-term pressures on online sales for Kefu Mei [1] - Kefu Mei's online sales performance during the first phase of Double Eleven was relatively weak, with an estimated year-on-year decline of 10% in online revenue for the second half of 2025, leading to an overall growth rate of approximately 5% for the year [1] - In contrast, Keli Jin is expected to achieve a high growth rate of about 40% in online revenue for the year, while offline business is projected to maintain steady growth [1] Group 2 - The company has adjusted its revenue growth forecast for Kefu Mei from a CAGR of 26% to 14.5% for the years 2025 to 2027 due to the anticipated short-term pressure on online sales [1] - Giant Bio's first injectable recombinant collagen product, recombinant type I α1 collagen lyophilized fiber, has been approved for market launch, aimed at facial dermal tissue filling to correct dynamic wrinkles, including frown lines, forehead lines, and crow's feet [1] - This approval signifies the completion of the company's full product matrix layout for aesthetic injections, post-surgical recovery dressings, and functional skincare [1] Group 3 - The company has two additional injectable collagen products currently in the approval stage: 1) Injectable recombinant collagen filler for moderate to severe neck wrinkles, prioritized for medical device approval by December 2024; 2) Recombinant collagen implant, with a registration application submitted in August 2025 as a drug-device combination, which has been accepted and is under review [2] - The approval of these products is expected to further enrich the company's aesthetic product matrix, covering a range of anti-aging scenarios from forehead to facial and neck areas, addressing dynamic wrinkle improvement to overall skin texture enhancement [2]

Core Points - The fifth Double Beauty CIC competition was successfully held in Beijing, showcasing the skills of medical aesthetics professionals [1] - The competition aimed to discover innovative and skilled medical aesthetics elites, focusing on rejuvenation techniques around the eyes and mouth [5][6] - The event gathered top experts and practitioners from both domestic and international backgrounds, promoting academic exchange and collaboration in the field of medical aesthetics [10][24] Group 1: Event Overview - The competition featured three main segments: sharing of rejuvenation plans for the eye and mouth areas, and practical clinical operations [9] - The event was attended by notable figures in the medical aesthetics field, including professors and directors from various prestigious institutions [3][8] - The theme of the competition was "Sculpting in Subtlety, Naturally Renewing Beauty," emphasizing the importance of innovation and skill in medical aesthetics [5][24] Group 2: Judging and Evaluation - The judging panel included prominent experts who evaluated participants based on theoretical knowledge, technical standards, innovation, and long-term effects [6][9] - The competition served as a platform for participants to enhance their professional skills and broaden their aesthetic knowledge [6][24] - The event highlighted the importance of standardization and knowledge transfer within the industry, with past champions now serving as mentors [6][12] Group 3: Awards and Recognition - The "Craftsmanship Beauty Team," led by Qian Jing, won the championship, demonstrating exceptional theoretical knowledge and clinical skills [16] - Awards were presented to various teams and individuals for their contributions to the competition and the field of medical aesthetics [18][20] - Special awards were given to international physicians for their recognition of Double Beauty's collagen products and their efforts in promoting international applications [14][22] Group 4: Future Directions - The event marked a significant milestone in the development of a systematic and scientific Eastern facial aesthetic treatment framework [24] - Double Beauty aims to continue its role as a leader in collagen applications, fostering international collaboration and advancing academic achievements in the field [10][24] - The company is committed to transforming the consensus reached during the event into actionable progress for the industry [24]

Core Insights - The collagen market is experiencing significant growth driven by increasing consumer focus on efficacy and ingredients, with two main growth drivers: professional skin care and aesthetic injection applications [1][3] - The collagen market in China is projected to exceed 16 billion yuan at the raw material level and approach 270 billion yuan at the retail level by 2030 [1] - The industry is currently in a phase of policy refinement, accelerated technological iteration, and tight collaboration across the supply chain [1] Industry Structure - The collagen industry has a high degree of integration between raw material supply and end product manufacturing, with upstream suppliers, midstream manufacturers of recombinant collagen, and downstream sales channels [2] - The market is characterized by significant growth potential, high technological barriers, and intense competition [2] End-User Applications - The demand for professional skin care products that combine medical safety and cosmetic efficacy is rapidly increasing, particularly in the aesthetic medicine sector [3] - Applications of collagen products are expanding from traditional moisturizing and nourishing functions to include core roles in aesthetic injection materials [3] Recommended Companies - Companies to watch include: Giant Bio (02367), Jinbo Bio (920982.BJ), Marubi Bio (603983.SH), Huaxi Bio (688363.SH), Fulejia (301371.SZ), Novozymes (688105.SH), Baipusais (301080.SZ), and Betaini (300957.SZ) [4]

Core Viewpoint - Lepu Medical's recent partnership with Meituan to promote its medical beauty brands "Yueyayan" and "Flora" is seen as a significant transformation effort amid ongoing performance pressures, but the path to success in the increasingly competitive medical beauty market is fraught with challenges [1][6]. Group 1: Financial Performance - Lepu Medical has experienced a continuous decline in performance, with a 23.52% year-on-year drop in revenue and an 80.37% decrease in net profit for 2024, marking the worst results in its 16-year history [2]. - The company recorded a goodwill and other asset impairment loss of 251 million yuan in 2024, with goodwill still amounting to 3.62 billion yuan, representing 14.35% of total assets as of mid-2025, indicating ongoing impairment risks [2]. Group 2: Market Competition - The medical beauty market is highly competitive, with Lepu Medical entering a saturated field where price wars are emerging, exemplified by New Oxygen's introduction of a 2,999 yuan "affordable童颜针" [3]. - Lepu Medical's recent launch of its self-developed polylactic acid facial filler (童颜针) positions it as the seventh product in this category in China, but the company faces significant challenges as a latecomer in a market dominated by established players [3]. Group 3: Diversification and Resource Allocation - In addition to medical beauty, Lepu Medical is diversifying into structural heart disease, GLP-1 innovative drugs, brain-computer interfaces, and artificial intelligence, reflecting its commitment to innovation [4]. - Despite a research and development expenditure of 1.249 billion yuan in 2024, the allocation across multiple emerging fields has resulted in insufficient investment in each area, leading to a strategic shift towards medical beauty amid tightening cash flow [4]. Group 4: Capital Structure Concerns - Lepu Medical, known for its aggressive acquisition strategy, has completed 54 investments and acquisitions from 2008 to 2021, resulting in high goodwill and asset impairment risks [5]. - As of mid-2025, the company's cash reserves have fallen to 3.6 billion yuan, while accounts receivable have risen to 2.05 billion yuan, significantly exceeding industry warning levels, indicating potential liquidity issues [5].

Investment Rating - The report does not explicitly state an investment rating for Giant Biogene, but it highlights the company's strong market position and potential for growth in the medical aesthetics sector. Core Insights - Giant Biogene's "Recombinant Type I α1 Collagen Lyophilized Fiber" received Class III Medical Device Registration from NMPA on October 21, 2024, marking its entry into the medical aesthetics injectables market [1][7]. - The approved Type I collagen is distinct from the Type III collagen already marketed by Jinbo Bio, allowing for unique product positioning [2][8]. - The product utilizes a long amino acid sequence (753 amino acids) and achieves high purity (99.9%), which are critical for its bioactivity and safety [3][9]. - The company has established a significant first-mover advantage with six operational production lines, exceeding ten tons of annual capacity, which supports rapid commercialization [4][10]. - The regulatory landscape for collagen injectables is stringent, with only 11 products approved from 7 companies, positioning Giant Biogene favorably against competitors [5][11]. - The approval paves the way for additional product applications, with two other medical aesthetic products currently under review [12]. Summary by Sections Product Approval - Giant Biogene's recombinant collagen product is approved for facial dermal tissue filling to correct dynamic wrinkles, showcasing the company's capabilities from R&D to commercial production [1][7]. Technical Differentiation - The company's collagen product is molecularly distinct from existing products, utilizing a specific amino acid sequence that does not form a triple-helical structure, reflecting advanced regulatory understanding [2][8]. - The proprietary molecular library of over 50 recombinant collagen molecules provides a solid foundation for future product iterations [3][9]. Production Capacity - The company has built a high-purity production line since 2021 and expanded its capacity to six lines, ensuring a robust supply chain for commercialization [4][10]. Market Landscape - The high regulatory barriers in the collagen injectables market favor established players like Giant Biogene, which benefits from superior biocompatibility and lower production costs compared to traditional animal-derived collagen [5][11]. Future Prospects - The approval of the current product is expected to accelerate the approval process for additional products, enhancing the company's product portfolio in the medical aesthetics market [12].

Macro Commentary - The core objective of China's "14th Five-Year Plan" (2026-2030) emphasizes high-quality development, shifting focus from GDP growth to technological self-reliance and economic transformation [2][4] - Key strategic industries highlighted include artificial intelligence, semiconductors, advanced robotics, green energy, aerospace, and industrial software [2] - The plan aims to rebalance the economy towards consumption-driven growth, with increased investment in social services such as healthcare and elder care, benefiting sectors like consumer staples and healthcare [2][4] Market Performance - The Hang Seng Index closed at 25,968, up 0.72% year-to-date performance is 29.45% [2] - The Shanghai Composite Index closed at 3,922, with a year-to-date increase of 17.03% [2] - U.S. markets showed positive performance, with the Dow Jones up 0.27% and the S&P 500 up 0.49% [2][4] Company Analysis - **Giant Bio (2367 HK)**: The approval of its first injectable aesthetic product marks the beginning of a new growth phase for the company. The product is aimed at facial dermal filling to correct dynamic wrinkles [5][6] - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic market, which is expected to drive growth [5] - **Thermo Fisher (TMO US)**: Reported a strong 3Q25 performance with a revenue increase of 5.0% year-on-year and an adjusted EPS growth of 9.7%. The company raised its full-year guidance based on robust performance [6][7] - The demand from pharma and biotech clients is showing positive signs, with revenue growth driven by bioproduction and analytical instruments [7][8] - The company is expected to benefit from the trend of pharmaceutical companies establishing manufacturing facilities in the U.S., which will reflect in its performance by 2027-2028 [9]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 58.35, down from a previous target of HKD 71.30, indicating a potential upside of 41.6% from the current price of HKD 41.20 [2][4]. Core Insights - The approval of the first injectable aesthetic product, recombinant type I α1 collagen, marks the beginning of a second growth curve for the company, expanding its product matrix in the aesthetic medicine sector [1][8]. - The Chinese aesthetic injection market is projected to reach RMB 147 billion by 2027, with the collagen injection segment expected to grow to RMB 16.8 billion, highlighting significant growth potential [8]. - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic medicine market, which is expected to drive growth from the new injectable products [8]. Financial Summary - Sales revenue is projected to grow from RMB 3,524 million in FY23A to RMB 8,715 million in FY27E, with a CAGR of approximately 17.7% [3][13]. - Net profit is expected to increase from RMB 1,451.8 million in FY23A to RMB 2,820.5 million in FY27E, reflecting a growth rate of 13.5% [3][13]. - The company’s net debt ratio is projected to increase from (57.2%) in FY23A to (73.4%) in FY27E, indicating a shift towards higher leverage [3][13]. Product Development - The company has two additional injectable collagen products in the approval stage, which are expected to enhance its aesthetic product portfolio and address various anti-aging needs [8][9]. - The newly approved injectable product is designed for facial dermal filling to correct dynamic wrinkles, positioning the company competitively in the market [9]. Market Position - The company has established a comprehensive product matrix that includes injectable products, post-surgery recovery dressings, and functional skincare, allowing it to capture a broader market share [1][8]. - The competitive landscape includes several other approved products, but the company’s strong distribution channels and brand recognition are expected to provide a competitive edge [8][9].